Hemab Therapeutics Holdings, Inc. (COAG)
Market Closed
10 Aug, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
49. 87
+0.21
+0.4229%
$
100.18M Market Cap
- P/E Ratio
- Div Yield
292,181 Volume
- Eps
$ 49.66
Previous Close 
Analysts:
Want to track COAG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Marketbeat | 2 months ago
